JP2013500726A5 - - Google Patents

Download PDF

Info

Publication number
JP2013500726A5
JP2013500726A5 JP2012523129A JP2012523129A JP2013500726A5 JP 2013500726 A5 JP2013500726 A5 JP 2013500726A5 JP 2012523129 A JP2012523129 A JP 2012523129A JP 2012523129 A JP2012523129 A JP 2012523129A JP 2013500726 A5 JP2013500726 A5 JP 2013500726A5
Authority
JP
Japan
Prior art keywords
polypeptide
amino acid
poly
complex
factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012523129A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013500726A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/044177 external-priority patent/WO2011014890A1/en
Publication of JP2013500726A publication Critical patent/JP2013500726A/ja
Publication of JP2013500726A5 publication Critical patent/JP2013500726A5/ja
Pending legal-status Critical Current

Links

JP2012523129A 2009-07-31 2010-08-02 改変第ix因子ポリペプチドおよびその使用 Pending JP2013500726A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23055109P 2009-07-31 2009-07-31
US61/230,551 2009-07-31
PCT/US2010/044177 WO2011014890A1 (en) 2009-07-31 2010-08-02 Modified factor ix polypeptides and uses thereof

Publications (2)

Publication Number Publication Date
JP2013500726A JP2013500726A (ja) 2013-01-10
JP2013500726A5 true JP2013500726A5 (enExample) 2013-09-12

Family

ID=43529743

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012523129A Pending JP2013500726A (ja) 2009-07-31 2010-08-02 改変第ix因子ポリペプチドおよびその使用

Country Status (21)

Country Link
US (1) US20120164130A1 (enExample)
EP (1) EP2461821A4 (enExample)
JP (1) JP2013500726A (enExample)
KR (1) KR20120060209A (enExample)
CN (1) CN102573890A (enExample)
AU (1) AU2010278721A1 (enExample)
BR (1) BR112012002072A2 (enExample)
CA (1) CA2769258A1 (enExample)
CL (1) CL2012000238A1 (enExample)
CR (1) CR20120052A (enExample)
CU (3) CU20120018A7 (enExample)
DO (1) DOP2012000030A (enExample)
EA (1) EA201290069A1 (enExample)
EC (1) ECSP12011637A (enExample)
GT (1) GT201200023A (enExample)
IN (1) IN2012DN00908A (enExample)
MX (1) MX2012001346A (enExample)
PE (1) PE20121643A1 (enExample)
SG (1) SG178119A1 (enExample)
WO (1) WO2011014890A1 (enExample)
ZA (1) ZA201200716B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2101821E (pt) 2006-12-15 2014-10-03 Baxter Int Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo
TR201813067T4 (tr) 2008-09-15 2018-09-21 Uniqure Biopharma B V Faktör IX polipeptit mutantı, bunun kullanımları ve bunu üretmeye yönelik bir yöntem.
EP3093029A1 (en) 2009-07-27 2016-11-16 Baxalta GmbH Blood coagulation protein conjugates
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
JP5909755B2 (ja) 2009-07-27 2016-04-27 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
ES2597954T3 (es) 2009-07-27 2017-01-24 Baxalta GmbH Conjugados de proteína de la coagulación sanguínea
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
TR201908836T4 (tr) * 2010-07-30 2019-07-22 Baxalta GmbH Oksim bağına yönelik nükleofilik katalizörler.
BR112013015898A2 (pt) 2010-12-22 2018-06-26 Baxter International Inc. derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada.
RU2617764C2 (ru) * 2011-12-19 2017-04-26 Дилафор Аб Неантикоагулянтные гликозаминогликаны, содержащие повторяющиеся дисахаридные звенья, и их медицинское применение
CA2892038C (en) * 2012-11-20 2021-12-28 Darrel W. Stafford Methods and compositions for modified factor ix proteins
US10105447B2 (en) * 2013-03-13 2018-10-23 Elanco Us Inc. Method of treating obesity in a companion animal comprising administering a modified canine leptin polypeptide
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
CN109789181A (zh) * 2016-07-27 2019-05-21 费城儿童医院 用于调节因子ix功能的组合物和方法
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
AU2019360270B2 (en) 2018-10-18 2025-08-07 Intellia Therapeutics, Inc. Compositions and methods for expressing factor IX.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044982A1 (en) * 2001-04-25 2003-03-06 Kenneth Chien Method to treat hemophilia by hepatic gene transfer of factor VIII/IX with vesicle vector
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
MXPA06006023A (es) * 2003-12-03 2006-08-23 Neose Technologies Inc Factor ix glicopegilado.
EP2423307A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IV polypeptides and use thereof for treatment
US7700734B2 (en) * 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof

Similar Documents

Publication Publication Date Title
JP2013500726A5 (enExample)
JP2012001560A5 (enExample)
Harris et al. Effect of pegylation on pharmaceuticals
JP2022500035A5 (enExample)
KR101309566B1 (ko) 히알루론산-단백질 컨쥬게이트 및 이의 제조 방법
EP1740608A2 (en) Modified human growth hormone polypeptides and their uses
JP2012532601A5 (enExample)
CN103068853A (zh) 协同性生物分子-聚合物轭合物
JP2003519478A5 (enExample)
CA2682147A1 (en) Modified fgf-21 polypeptides and their uses
CA2617064A1 (en) Conjugates of a g-csf moiety and a polymer
JP2006045243A (ja) N末端化学修飾タンパク質組成物および方法
IL169165A (en) Polymeric reagents and methods for the preparation thereof
JP2008509889A5 (enExample)
JP2012505917A5 (enExample)
CN101495536B (zh) 位点特异性聚乙二醇化的方法
JP2018515101A5 (enExample)
JP2007529539A5 (enExample)
CA2784800A1 (en) Modified porcine somatotropin polypeptides and their uses
EP2495258B1 (en) Catechol polyethylene glycol derivative and protein or peptide conjugates, and method for preparing same
Li et al. Synthesis of linear polyether polyol derivatives as new materials for bioconjugation
CA2784793A1 (en) Modified bovine somatotropin polypeptides and their uses
KR101042965B1 (ko) 카테콜 폴리에틸렌글리콜 유도체와 단백질 또는 펩타이드의 접합체 및 이의 제조방법
Cao et al. Dual-functionalized covalent triazine framework nanosheets as hierarchical nonviral vectors for intracellular gene delivery
Zhang et al. Helical nonfouling polypeptides for biomedical applications